Full text PDF - International Policy Network

292 Fighting the Diseases of Poverty
Neglected Diseases”, September 2001, available at http://www.accessmedmsf.org/documents/fatal_imbalance_2001.pdf
Muheki, C., McIntyre, D. & Barnes K., (2004), “Artemisinin-based combination
therapy reduces expenditure on malaria treatment in KwaZulu Natal, South
Africa,” Tropical Medicine and International Health 9, 959–966.
PAHO, (2006), “New malaria treatments guidelines issued,” 20/01/2006, available at
http://www.paho.org/English/DD/PIN/pr060120.htm.
Poisal, J. & Chulis, G., (2000), “Medicare beneficiaries and drug coverage,” Health
Affairs, 19(2).
Rice, A., West, K., & Black, R., (2004), “Vitamin A Deficiency” (Chapter 4), in Ezzati,
M. et al. (Eds.) Comparative Quantification of Health Risks. Geneva: World Health
Organization.
Shaw, R. & Ainswoth, M., (1995), “Financing heath services through user fees and
insurance,” World Bank discussion paper 294.
Soderlund, N. & Hansl, B., (2000), “Health Insurance in South Africa: an empirical
analysis of trends in risk-pooling and efficiency following deregulation,” Health
Policy and Planning, 15(4):378–385.
Trouiller et al., (2002), Drug development for neglected diseases: a deficient market and a
public-health policy failure, The Lancet, vol 359, June 22, 2002
Wirth, D., (2001), Survey for the Drugs for Neglected Diseases Working Group,
Switzerland, May 2001. [Online]. Original survey and letter available:
www.accessmed-msf.org. Andra Brichacek, Top 50 Pharmaceutical Companies of
2000, Pharmaceutical Executive, April 2001. Available: http://www.
pharmaportal.com/articles/pe/pe0401_062-82.pdf [2001, August 6].
Monath, T. & Nasidi, A., (1993), “Should Yellow Fever vaccine be included in the
expanded program of immunisation in Africa? A cost-effectiveness analysis for
Nigeria,” American Journal of Tropical Medicine and Hygiene, 48(2):274–299.
Moran, M., Ropars, A., Guzman, J. Diaz, J. & Garrison, C., (2005), “The New landscape
of neglected disease drug development,” London School of Economics
pharmaceutical R&D policy project, Wellcome Trust: London
Murray H., Pepin, J., Nutman, T., Hoffman, S., Mhamoud, A., (2001), “Recent
advances, tropical medicine”, British Medical Journal, 320:490–494
PhRMA, (2005), data solicited by author, November 2005.
Saleh, K. & Ibrahim, M., (2005), “Are Essential Medicines in Malaysia Accessible,
Affordable and Available?” Pharmacy World & Science, 27:6 442–446.
WHO, (1995), Global prevalence of Vitamin A deficiency, Micronutrient Deficiency
Information System working paper no.2, Geneva: WHO
WHO (1999), Report on Infectious Diseases: Removing Obstacles to Healthy Development,
Geneva: WHO.
WHO, (2002), World Health Report 2002, Geneva: WHO
WHO, (2002a), State of the world’s vaccines and immunisation, Geneva: WHO
WHO, (2003), World Health Report 2003, Geneva: WHO
WHO, (2003a), Medicines Strategy Report 2002–2003, Geneva: WHO
WHO, (2004), World Health Report, Statistical Annex, Geneva: WHO.
WHO, (2005a), Preventing Chronic Disease: a vital investment, Geneva: WHO.
WHO-IFPMA (2001) Round Table, Working paper on priority infectious diseases
requiring additional R&D, July 2001